You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High Risk Resectable

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Liver Metastases Trial in Shanghai (mFOLFOX6 + Cetuximab, mFOLFOX 6)

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • mFOLFOX6 + Cetuximab
  • mFOLFOX 6
  • Shanghai, China
    Zhongshan hosptial, Fudan University
Jul 14, 2023

Intrahepatic Cholangiocarcinoma Trial (procedure, drug, biological)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Biopsy
  • +7 more
  • (no location specified)
Sep 21, 2023

Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

Recruiting
  • Durvalumab
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jan 3, 2023

Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Dec 12, 2022

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 10, 2022

Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib Trial in Shanghai (drug, radiation, procedure)

Recruiting
  • Soft Tissue Sarcoma
  • +3 more
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Nov 1, 2022

High-Risk Resectable NSCLC Trial in Hangzhou (Nivolumab, Pembrolizumab)

Recruiting
  • High-Risk Resectable NSCLC
  • Nivolumab, Pembrolizumab
  • Hangzhou, China
    The Second Affiliated Hospital Zhejiang University School of Med
Oct 13, 2021

Intrahepatic Cholangiocarcinoma Trial in Hangzhou (Tislelizumab combined with GEMOX (GOT) regimen)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tislelizumab combined with GEMOX (GOT) regimen
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Sep 24, 2022

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,

Recruiting
  • Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Disitamab Vedotin Tislelizumab
  • Disitamab Vedotin
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 9, 2022

Melanoma Trial in Italy (Cobimetinib 20 MG Oral Tablet, Vemurafenib 240 Mg Oral Capsule, Atezolizumab 1200 MG in 20 ML

Recruiting
  • Melanoma
  • Cobimetinib 20 MG Oral Tablet
  • +2 more
  • Bagno A Ripoli, Firenze, Italy
  • +5 more
Apr 12, 2022

Colon Cancer Stage II, Colon Cancer Stage III Trial in Guangzhou (neoadjuvant chemoI, Colectomy, adjuvant chemo)

Recruiting
  • Colon Cancer Stage II
  • Colon Cancer Stage III
  • neoadjuvant chemotherapyI
  • +2 more
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
Jan 14, 2022

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab Nab paclitaxel)

Recruiting
  • High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Tislelizumab Nab paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Jun 9, 2022

Biliary Tract Cancer, Cholangiocarcinoma Trial in Italy (Gemcitabine, Nab paclitaxel, Cisplatin)

Not yet recruiting
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Ancona, Italy
  • +18 more
Sep 16, 2023

Non-metastatic Soft-tissue Sarcoma, Resectable Trial in France (Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the

Recruiting
  • Non-metastatic Soft-tissue Sarcoma
  • Resectable
  • Bordeaux, France
  • +9 more
Jul 27, 2022

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 Trial in Houston (biological,

Active, not recruiting
  • Prostate Adenocarcinoma
  • +5 more
  • Daratumumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma Trial in Lille (total pancreatectomy,

Recruiting
  • Adenocarcinoma of the Pancreas
  • +2 more
  • total pancreatectomy
  • intraportal islet autotransplantation
  • Lille, France
    Hop Claude Huriez Chu Lille
Mar 14, 2022

Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer Trial in Los Angeles,

Recruiting
  • Recurrent Skin Squamous Cell Carcinoma
  • +4 more
  • Cemiplimab
  • Resection
  • Los Angeles, California
  • +2 more
Nov 12, 2022

High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab-paclitaxel)

Recruiting
  • High-Risk
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Oct 22, 2021

Cutaneous Melanoma Trial in Houston (Atezolizumab)

Recruiting
  • Cutaneous Melanoma
  • Houston, Texas
    Houston Methodist Hospital
Dec 28, 2021

Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC

Active, not recruiting
  • Resectable Cholangiocarcinoma
  • +5 more
  • Atlanta, Georgia
  • +6 more
Oct 5, 2022

Resectable Hepatocellular Carcinoma Trial in Tianjin (Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w)

Recruiting
  • Resectable Hepatocellular Carcinoma
  • Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute and Hospital
Nov 3, 2021

Pancreatic Tumor Trial in Brussels (mFOLFIRINOX or gemcitabine-nabpaclitaxel)

Not yet recruiting
  • Pancreatic Neoplasm
  • mFOLFIRINOX or gemcitabine-nabpaclitaxel
  • Brussels, Belgium
    Hopital Erasme
Oct 15, 2021

Cutaneous Squamous Cell Carcinoma Trial in Italy (Cemiplimab)

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Bagno A Ripoli, Firenze, Italy
  • +6 more
Jul 27, 2022

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 5, 2021